{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:37:18Z","timestamp":1793633838792,"version":"4.5.1"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea government (Ministry of Science and ICT; MSIT)","award":["2023-01-07"],"award-info":[{"award-number":["2023-01-07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We aimed to evaluate the therapeutic potential of crizotinib, a broad-spectrum tyrosine kinase inhibitor against bladder cancer (BC) cells, based on a three-dimensional (3D) cell culture system. After proliferating cell masses (spheroids) using T24 cisplatin-na\u00efve and T24R2 cisplatin-resistant human BC cell lines, the spheroids were exposed to various crizotinib concentrations in order to derive an ideal crizotinib concentration to suppress cell survival, migration, and invasion. Crizotinib suppressed cell proliferation, migration, and invasion in both T24 and T24R2 BC cell lines under a 3D spheroid model, which was more appropriate than the conventional two-dimensional cell culture model. Real-time quantitative polymerase chain reaction analysis revealed a reduced expression of E-cadherin and an enhanced expression of vimentin, suggesting EMT suppression and the subsequent suppression of tumor aggressiveness following crizotinib administration. Meanwhile, the expressions of apoptosis-related genes increased. Western blot analysis revealed that the expression levels of phosphorylated mesenchymal\u2013epithelial transition factor (c-Met) and phosphorylated Akt decreased following crizotinib administration, suggesting that the antitumor effect of crizotinib can be associated with the inhibition of the phosphorylated activation of the c-Met\/PI3K\/Akt pathway. Crizotinib showed a potential antitumor effect on both cisplatin-na\u00efve and cisplatin-resistant human BC cells, likely through c-Met-induced PI3K\/Akt pathway inhibition.<\/jats:p>","DOI":"10.3390\/curroncol32040236","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T20:05:56Z","timestamp":1744920356000},"page":"236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the c-Met\/PI3K\/Akt Pathway in the Three-Dimensional Bladder Cancer Spheroid Model"],"prefix":"10.3390","volume":"32","author":[{"given":"Byeongdo","family":"Song","sequence":"first","affiliation":[{"name":"Department of Urology, Hanyang University Guri Hospital, 153, Gyeongchun-ro, Guri-si 11923, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhyo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul National University Bundang Hospital, 166, Gumi-ro, Bundang-gu, Seongnam-si 13620, Gyunggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Nyoung","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul National University Bundang Hospital, 166, Gumi-ro, Bundang-gu, Seongnam-si 13620, Gyunggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Hung","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul National University Bundang Hospital, 166, Gumi-ro, Bundang-gu, Seongnam-si 13620, Gyunggi-do, Republic of Korea"},{"name":"Department of Urology, Vinmec International Hospital, 458 P. Minh Khai, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangchul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul National University Bundang Hospital, 166, Gumi-ro, Bundang-gu, Seongnam-si 13620, Gyunggi-do, Republic of Korea"},{"name":"Department of Urology, Seoul National University College of Medicine, 71, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.01.002","article-title":"Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer","volume":"54","author":"Buttigliero","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4111\/icu.20230006","article-title":"Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies","volume":"64","author":"Kim","year":"2023","journal-title":"Investig. Clin. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jare.2021.11.010","article-title":"Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives","volume":"39","author":"Liu","year":"2022","journal-title":"J. Adv. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.euf.2019.10.016","article-title":"Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer","volume":"6","author":"Motterle","year":"2020","journal-title":"Eur. Urol. Focus."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00228-019-02771-5","article-title":"Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity","volume":"76","author":"Casanova","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urolonc.2017.12.018","article-title":"Recent developments in the treatment of advanced bladder cancer","volume":"36","author":"Godwin","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.urology.2006.12.003","article-title":"Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens\u2014Evidence of schedule-dependent synergy","volume":"69","author":"McHugh","year":"2007","journal-title":"Urology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Peng, M., Xiao, D., Bu, Y., Long, J., Yang, X., Lv, S., and Yang, X. (2021). Novel Combination Therapies for the Treatment of Bladder Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.539527"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-022-04459-7","article-title":"An update on antibody-drug conjugates in urothelial carcinoma: State of the art strategies and what comes next","volume":"90","author":"Chapman","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.18.02257","article-title":"Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?","volume":"37","author":"Tannock","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/icb.2016.126","article-title":"Targeting cancer-related inflammation in the era of immunotherapy","volume":"95","author":"Nakamura","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2147\/CMAR.S369175","article-title":"c-Met: A Promising Therapeutic Target in Bladder Cancer","volume":"14","author":"Feng","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/s41388-020-01577-5","article-title":"The role of MET in chemotherapy resistance","volume":"40","author":"Wood","year":"2021","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kitowska, K., Gorska-Arcisz, M., Antoun, D., Zarczynska, I., Czaplinska, D., Szczepaniak, A., Skladanowski, A.C., Wieczorek, M., Stanczak, A., and Skupinska, M. (2021). MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.633410"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2217\/fon.14.314","article-title":"Crizotinib in the management of advanced-stage non-small-cell lung cancer","volume":"11","author":"Loong","year":"2015","journal-title":"Future Oncol."},{"key":"ref_28","first-page":"djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Farina","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.3934\/mbe.2019296","article-title":"Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review","volume":"16","author":"Hou","year":"2019","journal-title":"Math. Biosci. Eng."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1111\/jog.15003","article-title":"Crizotinib-induced anti-cancer activity in human cervical carcinoma cells via ROS-dependent mitochondrial depolarization and induction of apoptotic pathway","volume":"47","author":"Varma","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_31","first-page":"817","article-title":"Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma","volume":"43","author":"Chen","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-20-2306","article-title":"Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib","volume":"26","author":"Tripathi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers6042313","article-title":"Characterization of HGF\/Met Signaling in Cell Lines Derived from Urothelial Carcinoma of the Bladder","volume":"6","author":"Lee","year":"2014","journal-title":"Cancers"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12935-023-03069-4","article-title":"Bladder cancer: Therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics","volume":"23","author":"Farouk","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1464-410X.2005.05472.x","article-title":"Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities","volume":"95","author":"Byun","year":"2005","journal-title":"BJU Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3892\/or.2023.8567","article-title":"CUDC-907 suppresses epithelial-mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer","volume":"49","author":"Ho","year":"2023","journal-title":"Oncol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bellmunt, J., Selvarajah, S., Rodig, S., Salido, M., de Muga, S., Costa, I., Bellosillo, B., Werner, L., Mullane, S., and Fay, A.P. (2014). Identification of ALK gene alterations in urothelial carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103325"},{"key":"ref_38","first-page":"83","article-title":"Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: Patients selection and perspectives","volume":"7","author":"Fallet","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Amaral, R.L.F., Miranda, M., Marcato, P.D., and Swiech, K. (2017). Comparative Analysis of 3D Bladder Tumor Spheroids Obtained by Forced Floating and Hanging Drop Methods for Drug Screening. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00605"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Nunes, A.S., Costa, E.C., Barros, A.S., de Melo-Diogo, D., and Correia, I.J. (2019). Establishment of 2D Cell Cultures Derived From 3D MCF-7 Spheroids Displaying a Doxorubicin Resistant Profile. Biotechnol. J., 14.","DOI":"10.1002\/biot.201800268"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2020.08.075","article-title":"Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines","volume":"533","author":"Muguruma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Balma\u00f1a, M., Diniz, F., Feij\u00e3o, T., Barrias, C.C., Mereiter, S., and Reis, C.A. (2020). Analysis of the Effect of Increased \u03b12,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030722"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"51675","DOI":"10.18632\/oncotarget.18386","article-title":"Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells","volume":"8","author":"Schroeder","year":"2017","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Berrouet, C., Dorilas, N., Rejniak, K.A., and Tuncer, N. (2020). Comparison of Drug Inhibitory Effects (IC50) in Monolayer and Spheroid Cultures. Bull. Math. Biol., 82.","DOI":"10.1007\/s11538-020-00746-7"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.clgc.2016.07.021","article-title":"Epithelial-To-Mesenchymal Transition and Its Correlation with Clinicopathologic Features in Patients with Urothelial Carcinoma of the Bladder","volume":"15","author":"Singh","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","article-title":"The genetic basis of cancer of the kidney","volume":"170","author":"Linehan","year":"2003","journal-title":"J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00262-003-0474-8","article-title":"Apoptosis pathways in cancer and cancer therapy","volume":"53","author":"Debatin","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/156800908783769391","article-title":"Targeting cell death in tumors by activating caspases","volume":"8","author":"MacKenzie","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Bladder Cancer","volume":"1655","author":"Sathe","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17059","DOI":"10.18632\/oncotarget.15001","article-title":"Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K\/AKT and ERK\/MMP signaling","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5306\/wjco.v7.i6.425","article-title":"Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer","volume":"7","author":"Deben","year":"2016","journal-title":"World J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:16:42Z","timestamp":1760030202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040236"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040236","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}